Literature DB >> 22330922

Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis.

J Meletiadis1, E Mavridou, W J G Melchers, J W Mouton, P E Verweij.   

Abstract

Epidemiological cutoff values (ECV) are commonly used to separate wild-type isolates from isolates with reduced susceptibility to antifungal drugs, thus setting the foundation for establishing clinical breakpoints for Aspergillus fumigatus. However, ECVs are usually determined by eye, a method which lacks objectivity, sensitivity, and statistical robustness and may be difficult, in particular, for extended and complex MIC distributions. We therefore describe and evaluate a statistical method of MIC distribution analysis for posaconazole, itraconazole, and voriconazole for 296 A. fumigatus isolates utilizing nonlinear regression analysis, the normal plot technique, and recursive partitioning analysis incorporating cyp51A sequence data. MICs were determined by using the CLSI M38-A2 protocol (CLSI, CLSI document M38-A2, 2008) after incubation of the isolates for 48 h and were transformed into log(2) MICs. We found a wide distribution of MICs of all azoles, some ranging from 0.02 to 128 mg/liter, with median MICs of 32 mg/liter for itraconazole, 4 mg/liter for voriconazole, and 0.5 mg/liter for posaconazole. Of the isolates, 65% (192 of 296) had mutations in the cyp51A gene, and the majority of the mutants (90%) harbored tandem repeats in the promoter region combined with mutations in the cyp51A coding region. MIC distributions deviated significantly from normal distribution (D'Agostino-Pearson omnibus normality test P value, <0.001), and they were better described with a model of the sum of two Gaussian distributions (R(2), 0.91 to 0.96). The normal plot technique revealed a mixture of two populations of MICs separated by MICs of 1 mg/liter for itraconazole, 1 mg/liter for voriconazole, and 0.125 mg/liter for posaconazole. Recursive partitioning analysis confirmed these ECVs, since the proportions of isolates harboring cyp51A mutations associated with azole resistance were less than 20%, 20 to 30%, and >70% when the MICs were lower than, equal to, and higher than the above-mentioned ECVs, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330922      PMCID: PMC3346643          DOI: 10.1128/AAC.05959-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Multiple-triazole-resistant aspergillosis.

Authors:  Paul E Verweij; Emilia Mellado; Willem J G Melchers
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

2.  In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.

Authors:  Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates.

Authors:  Hanneke A de Valk; Jacques F G M Meis; Ilse M Curfs; Konrad Muehlethaler; Johan W Mouton; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

5.  A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

Authors:  E Mellado; G Garcia-Effron; L Alcázar-Fuoli; W J G Melchers; P E Verweij; M Cuenca-Estrella; J L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

6.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.

Authors:  M Murphy; E M Bernard; T Ishimaru; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

8.  Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.

Authors:  Adriana M Nascimento; Gustavo H Goldman; Steven Park; Salvatore A E Marras; Guillaume Delmas; Uma Oza; Karen Lolans; Michael N Dudley; Paul A Mann; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

9.  Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species.

Authors:  E Mellado; T M Diaz-Guerra; M Cuenca-Estrella; J L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

10.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

Authors:  D W Denning; S A Radford; K L Oakley; L Hall; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

View more
  19 in total

1.  The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.

Authors:  Giorgia Valsesia; Michael Hombach; Florian P Maurer; Patrice Courvalin; Malgorzata Roos; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

2.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination.

Authors:  J Meletiadis; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Validation of antibiotic susceptibility testing guidelines in a routine clinical microbiology laboratory exemplifies general key challenges in setting clinical breakpoints.

Authors:  Michael Hombach; Patrice Courvalin; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

Review 4.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

5.  Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values.

Authors:  A Espinel-Ingroff; J Turnidge; A Alastruey-Izquierdo; E Dannaoui; G Garcia-Effron; J Guinea; S Kidd; T Pelaez; M Sanguinetti; J Meletiadis; F Botterel; B Bustamante; Y-C Chen; A Chakrabarti; A Chowdhary; E Chryssanthou; S Córdoba; G M Gonzalez; J Guarro; E M Johnson; J V Kus; C Lass-Flörl; M J Linares-Sicilia; E Martín-Mazuelos; C E Negri; M A Pfaller; A M Tortorano
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method.

Authors:  Emilia Cantón; Javier Pemán; David Hervás; Carmen Iñiguez; David Navarro; Julia Echeverría; José Martínez-Alarcón; Dionisia Fontanals; Bárbara Gomila-Sard; Buenaventura Buendía; Luis Torroba; Josefina Ayats; Angel Bratos; Ferran Sánchez-Reus; Isabel Fernández-Natal
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

7.  Analysis of promoter function in Aspergillus fumigatus.

Authors:  Sanjoy Paul; J Stacey Klutts; W Scott Moye-Rowley
Journal:  Eukaryot Cell       Date:  2012-07-27

8.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; C Lass-Flörl; E Martin-Mazuelos; J Meis; T Peláez; M A Pfaller; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

9.  Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.

Authors:  Imke H Bartelink; Tom Wolfs; Martine Jonker; Marjolein de Waal; Toine C G Egberts; Tessa T Ververs; Jaap J Boelens; Marc Bierings
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

10.  Involvement of the opportunistic pathogen Aspergillus tubingensis in osteomyelitis of the maxillary bone: a case report.

Authors:  Erik Bathoorn; Natalia Escobar Salazar; Shahrzad Sepehrkhouy; Martin Meijer; Hans de Cock; Pieter-Jan Haas
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.